Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-09-05
2008-10-21
Belyavskyi, Michail (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S387100, C530S388200, C530S388730
Reexamination Certificate
active
07438910
ABSTRACT:
Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
REFERENCES:
patent: 4968607 (1990-11-01), Dower et al.
patent: 5081228 (1992-01-01), Dower et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5296592 (1994-03-01), Dower et al.
patent: 5319071 (1994-06-01), Dower et al.
patent: 5488032 (1996-01-01), Dower et al.
patent: 5492888 (1996-02-01), Dower et al.
patent: 6248516 (2001-06-01), Winter et al.
patent: 6511665 (2003-01-01), Dower et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 7115717 (2006-10-01), Mori et al.
patent: 7132281 (2006-11-01), Hanson et al.
patent: 7202343 (2007-04-01), Gudas et al.
patent: 7217796 (2007-05-01), Wang et al.
patent: 2003/0086930 (2003-05-01), Mueller et al.
patent: 2004/0063913 (2004-04-01), Gram et al.
patent: 2005/0084449 (2005-04-01), Landes et al.
patent: 2006/0275211 (2006-12-01), Jakobovits et al.
patent: 2007/0116708 (2007-05-01), Gudas et al.
patent: 2007/0292411 (2007-12-01), Salcedo et al.
patent: 623674 (1988-11-01), None
patent: 0623674 (1994-11-01), None
patent: 2002512776 (2002-05-01), None
patent: 2005536534 (2005-12-01), None
patent: 97/07671 (1997-03-01), None
patent: 01/09187 (2001-02-01), None
patent: 01/09187 (2001-02-01), None
patent: 02/16436 (2002-02-01), None
Janeway et al. Immunobiology 3rdEd., p. 3:1-3:3, Garland Publishing, Inc., New York (1997).
Rudikoff, et al., Proc. Natl. Acad. Sci. USA 79: 1979-1983 (1982).
Harlow et al. Antibodies, p. 76, Cold Spring Harbor Press, New York (1988).
Abbas et al. Cellular and Molecular Immunology 5thEd., p. 144, Saunders Publishing, Philapelphia, 2003.
Vigers et al., Nature. Mar. 13, 1997;386(6621):190-4.
Janeway et al., Immunobiology, 5th Ed., Garland Science, pp. 94-105 (2001).
Colman P. M., Research in Immunology, 145:33-36, 1994.
Chien et al., Proc Natl Acad Sci U S A. Jul. 1989;86(14):5532-6.
Schreuder et al., Nature. Mar. 13, 1997;386(6621):194-200.
Barbas et al., “Human autoantibody recognition of DNA”, Proc Natl Acad Sci U S A. Mar. 28, 1995;92(7):2529-33.
Beiboer et al., “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent”, J Mol Biol. Feb. 25, 2000;296(3):833-49.
Desiderio A et al., “A semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold”,J. Mol. Biol. 2001; 310, 603-615.
Desmyter A, et al., “Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody”,The Journal of Biological Chemistry2001; vol. 276, No. 28, pp. 26285-26290.
Ditzel et al., “Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection”, J Immunol. Jul. 15, 1996;157(2):739-49.
Klimka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning”, Br J Cancer. Jul. 2000;83(2):252-60.
Rader et al., “A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries”, Proc Natl Acad Sci U S A. Jul. 21, 1998;95(15):8910-5.
Schier R, et al., “Isolation of Picomolar Affinity Anti-c-erbB-2 Single-Chain Fv by Molecular Evolution of the Complementarity Determing Regions in the Center of the Antibody Binding Site”,J. Mol. Biol. 1996; 263, 551-567.
GenBank Accession CAD35492.1 (Jun. 18, 2002).
GenBank Accession AAM46660.1 (Aug. 20, 2002).
Edinger et al., 2000, Characterization of epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein, J. Virol., 74(17): 7922-7935.
Sims John E. et al., 1993, Interleukin-1 signaling occurs exclusively via the type 1 receptor, PNAS, 90(13): 6155-6159.
Purified rat anti-mouse CD121a(IL receptor, type 1, p80) monoclonal antibody (no azide/ low endotoxin), Technical Data Sheet BD Pharmingen, Jun. 2003, (Jun. 2003), p. 1.
Choe JY et al., 2003, Interleukin-1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J. Experimental Medicine , Tokyo JP, 197(4): 537-542.
Fredericks ZL et al., 2004, Identification of potent human anti-IL-IP1 antagonist antibodies, Protein Engineering, Design and Selection, Oxford Journal, London, 17(1): 95-106.
Search Report from related European application.
Search Report from related Taiwanese application.
International Search Report from related International application.
Kay, B. et al, (1993) An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets, Gene, vol. 128 (1): pp. 59-65.
Greenfeder et al. (1995) Molecular Cloning and Charaterization of a second Subunit of the Interleukin 1 Receptor Complex, J. Biol. Chem., vol. 270; pp. 13757-13766.
Yoon and Dinarello (1998) Antibodies to Domains II and III of the IL-1 Receptor Accessory Protein Inhibit IL-1b Activity but not Binding: Regulation of IL-1 Responses is Via Type i Receptor, Not the Accessory Protein, J. Immunology. vol. 160; pp. 3170-3179.
Cullinan, et al. (1998) IL-1 Receptor Accessory Protein is an Essential Component of the IL-1 Receptor, J. Immunol., vol. 161; pp. 5614-5620.
Wesche, et al. (1998) Effects of IL-1 receptor accessory protein on IL-1 binding, FEBS Lett., vol. 429; pp. 303-306.
D'Ettorre, et al. (1997) Functional epitope mapping of human interleukin-1b by surface plasmon resonance, Eur. Cytokine Netw., vol. 8, No. 2; pp. 161-171.
Dripps, et al. (1991) Interleukin-1 (IL-1) Receptor Antagonist Binds to the 80-kDa IL-1 Receptor but Does not Initiate IL-1 Signal Transduction, J. Biol. Chem. vol. 266 No. 16; pp. 10331-10336.
Dripps, et al. (1991) Interleukin-1 Receptor Antagonist Binds to the Type II Interleukin-1 Receptor on B Cells and Neutrophils, J. Biol. Chem. vol. 266 No. 30; pp. 20331-20315.
Walsh, B. J. and Howden, M.E.H. (1989) A method for the detection of IgE binding sequences of allergens based on a modification of epitope mapping, Journal of Immunological Methods, vol. 121, Issue 2, pp. 275-280.
Airenne, K.J. et al. (1999) Recombinant avidin and avidin-fusion proteins, Biomolecular Engineering, vol. 16, Issues 1-4, pp. 87-92.
McIntyre, K. W. et al (1991) Inhibition of Interleukin 1 (IL-1) Binding and Bioactivity InVitro and Modulation of Acute Inflammation InVivo by IL-1 Receptor Antagonist and Anti-IL-1 Receptor Monoclonal Antibody, J. Exp. Med. vol. 173, pp. 931-939.
Goldsby, R.A., et al. (2003) Immunology, 5th ed., W.H. Freeman and Co., p. 83.
Rogers, et al., (1992) Proc Natl Acad Sci USA vol. 89, pp. 1011-1015.
Probert, et al., (1995) Eur J Immunol., vol. 25, pp. 1794-1797.
Chizzonite, et al., (1989) Proc Natl Acad Sci USA vol. 86, pp. 8029-8033.
Williams, et al., (2000) J Immunol., vol. 165, pp. 7240-7245.
Search Report from related Japanese application.
McMahan, et al. EMBO J (1991) vol. 10, No. 10, pp. 2821-2832.
Neta, et al., Blood (1990) vol. 76, No. 1, pp. 57-62.
Oldenburg, et al., Cytokine (1995) vol. 7, No. 6, pp. 510-516.
Schafers, et al., Neuroscience Letters (2001) vol. 310, pp. 113-116.
Edinger et al., 2000, Characterization of epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein, J. Virol., 74(17): 7922-7935.
Sims John E. et al., 1993, Interleukin-1 signaling occurs exclusively via the type 1 receptor, PNAS, 90(13): 6155-6159.
Purified rat anti-mouse CD121a (IL receptor, type 1, p80) monoclonal antibody (no azide/ low endotoxin), Technical Data Sheet BD Pharmingen, Jun. 2003, (Jun. 2003), p. 1.
Choe JY et al., 2003, Interleukin-1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J. Experiment
Elliott Gary
Huang Haichun
Martin Francis Hall
Qian Xueming
Varnum Brian
Amgen Inc.
Belyavskyi Michail
McDonnell Boehnen & Hulbert & Berghoff LLP
Medarex Inc.
Skelding Zachary
LandOfFree
Therapeutic human anti-IL1-R1 monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic human anti-IL1-R1 monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic human anti-IL1-R1 monoclonal antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002329